Home  |  Contact

UniProtKB/Swiss-Prot O60762: Variant p.Arg92Gly

Dolichol-phosphate mannosyltransferase subunit 1
Gene: DPM1
Variant information

Variant position:  92
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Arginine (R) to Glycine (G) at position 92 (R92G, p.Arg92Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Congenital disorder of glycosylation 1E (CDG1E) [MIM:608799]: A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1E patients have features consistent with a dystroglycanopathy and congenital muscular dystrophy, including O-mannosylation defect, camptodactyly, elevated creatine kinase, motor delay and dystrophic changes on muscel biopsy. {ECO:0000269|PubMed:10642597, ECO:0000269|PubMed:10642602, ECO:0000269|PubMed:15669674, ECO:0000269|PubMed:23856421}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In CDG1E.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  92
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  260
The length of the canonical sequence.

Location on the sequence:   RDVAEQLEKIYGSDRILLRP  R EKKLGLGTAYIHGMKHATGN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         RDVAEQLEKIYGSDRILLRPREKKLGLGTAYIHGMKHATGN

Mouse                         REVAEQLAEIYGPDRILLRPREKKLGLGTAYIHGIKHATGN

Pig                           RDIAEQLVKIYGSDKILLRPREKKLGLGTAYIHGMKHATGN

Bovine                        RDVAEQLEKIYGSDRILLRPREKKLGLGTAYIHGMKHATGN

Drosophila                    LDVAKDLQKIYGEDKIVLRPRGSKLGLGTAYIHGIKHATGD

Slime mold                    LEVAQQLQKIYGEEKIKILSRPGKMGLGSAYMDGIKKSTGN

Baker's yeast                 VEEVDALAHQGYNVRIIVRTNER--GLSSAVLKGFYEAKGQ

Fission yeast                 QEVAKELQKIYGEDKILLKPRSGKLGLGTAYIHGLKFATGD

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 260 Dolichol-phosphate mannosyltransferase subunit 1


Literature citations

Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie).
Kim S.; Westphal V.; Srikrishna G.; Mehta D.P.; Peterson S.; Filiano J.; Karnes P.S.; Patterson M.C.; Freeze H.H.;
J. Clin. Invest. 105:191-198(2000)
Cited for: VARIANT CDG1E GLY-92;

Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie.
Imbach T.; Schenk B.; Schollen E.; Burda P.; Stutz A.; Gruenewald S.; Bailie N.M.; King M.D.; Jaeken J.; Matthijs G.; Berger E.G.; Aebi M.; Hennet T.;
J. Clin. Invest. 105:233-239(2000)
Cited for: VARIANT CDG1E GLY-92;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.